CytoMed Reports Increased Net Loss and Rapid Cash Burn Amidst Clinical Progress and Strategic Expansion
Summary
CytoMed Therapeutics reported a widened net loss and a significant drop in cash, highlighting financial distress, despite progress in its clinical trials and strategic corporate initiatives.
Key Events
-
Increased Net Loss
The company's audited net loss for the financial year ended December 31, 2025, increased to US$3.11 million, up from US$1.96 million in 2024.
-
Significant Cash Burn
Cash and bank balances decreased substantially to US$1.63 million as of December 31, 2025, from US$3.87 million in 2024, indicating a rapid depletion of liquidity.
-
Clinical Trial Advancement
The ANGELICA CAR-T Phase I clinical trial in Singapore has proceeded to dose level 2 and is soon escalating to the final dose level 3, with target completion by year-end.
-
Strategic Expansion and Research Validation
CytoMed entered an MOU for a new Phase I clinical trial in Malaysia, acquired a Malaysian cord blood bank, and co-authored a preclinical study with MD Anderson Cancer Center suggesting potential for its allogeneic γδ T cell therapy in treating AML.
Analysis
CytoMed Therapeutics reported a significant increase in its net loss and a substantial reduction in cash balances for the full year 2025, which underpins the going concern warning disclosed in its concurrently filed 20-F. The company's cash position of US$1.63 million against a burn rate of over US$2 million raises immediate concerns about its financial runway. While the advancement of clinical trials and strategic acquisitions are positive developments for the long-term, the severe financial deterioration presents a critical challenge for the company's near-term viability. Investors should closely monitor the company's ability to secure additional funding to support its operations and ongoing clinical programs.
At the time of this filing, GDTC was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12M. The 52-week trading range was $0.73 to $3.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.